CD40 and neoplasm: Agonists lead to observable T cell activation and anti-tumor potentiation induced by dendritic cells, and it has been well established that CD40-signaling can potentiate the ncNF-κB pathway and that a CD40-blockade inhibits dendritic-cell induced HIV latency reversal.